B-Cell Activation by Crosslinking of Surface Igm Or Ligation of CD40 Involves Alternative Signal Pathways and Results in Different B-Cell Phenotypes HENRY H

Total Page:16

File Type:pdf, Size:1020Kb

B-Cell Activation by Crosslinking of Surface Igm Or Ligation of CD40 Involves Alternative Signal Pathways and Results in Different B-Cell Phenotypes HENRY H Proc. Natl. Acad. Sci. USA Vol. 92, pp. 3348-3352, April 1995 Immunology B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes HENRY H. WORTIS*t, MARK TEUTSCH*, MINDY HIGER*, JENNY ZHENG*, AND DAVID C. PARKERt§ *Department of Pathology, Tufts University School of Medicine, and Graduate Program in Immunology, Sackler School of Graduate Biomedical Sciences, Boston, MA 02111; and tDepartment of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester, MA 01655 Communicated by Salome G. Waelsch, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY December 7, 1994 ABSTRACT Treatment of small resting B cells with sol- direct contact with an activated T-helper cell such that the uble F(ab')2 fragments of anti-IgM, an analogue of T-inde- surface molecule gp39 [CD40 ligand (CD40L)] of the T cell pendent type 2 antigens, induced activation characterized by ligates the CD40 of the B cell (10). proliferation and the expression of surface CD5. In contrast, Our strategy to determine if minimal TD and TI-2 signals B cells induced to proliferate in response to thymus-dependent were sufficient to induce phenotypic differences in B cells was inductive signals provided by either fixed activated T-helper 2 to use an antigen that could be modified so as to initiate either cells or soluble CD40 ligand-CD8 (CD40L) recombinant pro- a TD or a TI-2 response. To produce a TD response we used tein displayed elevated levels of CD23 (FcJII receptor) and no monovalent Fab of rabbit anti-IgM and provided help in the surface CD5. Treatment with anti-IgM and CD40L induced form of the clone CDC35, a T-helper 2 line known to provide higher levels of proliferation and generated a single popula- help to B cells that have bound, processed, and presented tion ofB cells coexpressing minimal amounts ofCD5 and only rabbit Fab in the context of IAd (9, 11). To provide the a slight elevation ofCD23. Anti-IgM- but not CD40L-mediated equivalent of a TI-2 signal we used the divalent F(ab')2 form activation was highly sensitive to inhibition by cyclosporin A of the same antibody. We then compared the surface pheno- and FK520. Sp-cAMPS, an analogue of cAMP, augmented types of the responding B cells. CD40L and suppressed surface IgM-mediated activation. We followed up these initial experiments with others using Taken together these results are interpreted to mean that fixed, preactivated helper T cells as B-cell activators (12). This there is a single population of small resting B cells that can allowed us to examine the phenotype of B cells activated by respond"to either T-independent type 2 (surface IgM)- or T-helper cells in the absence of interleukins. Finally, we T-dependent (CD40)-mediated activation. In response to dif- examined the phenotype of B cells stimulated by a soluble ferent intracellular signals these cells are induced to enter fusion protein containing the CD40L (13) so as to directly alternative differentiation pathways. compare the phenotypes and the signaling pathways involved in minimal TI-2 [F(ab')2 anti-IgM] and TD (CD40L) re- Though it has been suggested that T-cell-independent (TI) and sponses. Our experiments led us to the conclusion that a single thymus-dependent (TD) responses (1) might be generated population of B cells can respond to either sIgM or CD40 from different B-cell precursors (2), the weight of evidence ligation using alternative signal pathways to generate activated suggests that a given B cell can enter either the TI or TD B cells of different phenotypes. pathway (3-5). We wanted to directly determine if B cells exist as two precursor populations or if there is a single population MATERIALS AND METHODS- that can be induced to enter alternative differentiation path- ways. If the latter proved to be the case, we wanted to Mice. Experiments involving CDC35 cells were done with determine if the minimal inductive events were sufficient to cells from BALB/c/J mice purchased from The Jackson induce phenotypic differences in responding cells. To study Laboratory. Others were done using cells from CBA/HHW or this we chose to use anti-IgM antibody as an experimental CBA/HHW.Ighb mice (14). analogue of one type of TI antigen. TI antigens are divided into Cells. Cells of the T-helper 2 line CDC35 were used 2-3 type 1, which are intrinsically mitogenic [such as lipopolysac- weeks after their last stimulation. B cells were partially purified charide (LPS) in the mouse], and type 2, which are nonmito- as described (15). Activated CDC35 T cells were generated by genic repeating unit molecules such as polysaccharides or their incubating cells at 1 x 106 per ml for 24 hr on plates precoated haptenated derivatives (6). TI-2 activation is initiated by the with anti-CD3 (145-2C11). The activated cells were then crosslinking of surface immunoglobulin (slg) followed by a washed three times in phosphate-buffered saline and fixed with cascade of events that includes cytoplasmic tyrosine kinases, a 0.4% fresh paraformaldehyde for 5 min (12). Fixed cells were Ca2+ flux, and the catalytic activity of protein kinase C (PKC) kept in tissue culture medium at 4°C. The supernate generated (reviewed in ref. 7). The F(ab')2 fragments of antibody to by these activated T cells was harvested and stored frozen. mouse 1gM can bind to B-cell sIgM so as to effect its B-Cell Culture and Stimulation. Cells were cultured in RPMI crosslinking and thereby can provide a polyclonal B-cell acti- 1640 medium supplemented as described (15). A polyclonal vating signal equivalent to a TI-2 antigen (8). rabbit anti-mouse IgM was prepared as Fab and F(ab')2 frag- Unlike TI-2 responses, a TD response does not require sIg ments as described (9). For experiments involving immunosup- crosslinking, as even monomeric antigen can be bound, endo- pressants we prepared F(ab')2 fragments from goat anti-(MOPC- cytosed, processed, and presented in the context of major histocompatibility complex class II for T-helper cell recogni- Abbreviations: CsA, cyclosporin A; LPS, lipopolysaccharide; FKBP, tion and activation followed ultimately by T-cell-mediated FK506 binding protein; CD40L, CD40 ligand; TD, thymus-dependent; activation of B cells (9). The crucial TD signal is provided by TI, T-cell-independent; sIg, surface Ig; IL, interleukin; PK, protein kinase. tTo whom reprint requests should be addressed. The publication costs of this article were defrayed in part by page charge §Present address: Department of Molecular Microbiology and Immu- payment. This article must therefore be hereby marked "advertisement" in nology, Oregon Health Science University, 3181 S.W. Sam Jackson accordance with 18 U.S.C. §1734 solely to indicate this fact. Park Road, L220-Portland, OR 97201. 3348 Downloaded by guest on September 29, 2021 Immunology: Wortis et al Proc. Natl. Acad. Sci. USA 92 (1995) 3349 Table 1. Proliferation of small resting splenic B cells Fixed CD40L Fab F(ab')2 T T cells Fixed T cells + Exp. Medium anti-IgM anti-IgM cells + Fab SN T cells + SN CD40L LPS F(ab')2 DS-4 0.3* 1.2 17.7 42.0 DS-9 1.2 5.8 45.2 J180 [2.3] 2.7 12.7 96.5 [4.6] 22.9 42.9 96.6 J185 8.1 12.5 14.9 83.1 129.6 J181 0.2 0.2 1.6 25.1 15.1 85.6 117t 3.2 78.0 42.5 108.6 123t 1.6 13.8 37.6 85.8 SA 3.1 101.3 52.0 120.8 200.2 SN, supernate. *[3H]Thymidine at 60 hr (42 hr in experiments marked t) expressed as the geometric mean of triplicate values of cpm x 10-3. SEM were -x/1.2 for all values -2 x 103 cpm except for the values in experiment J180 (shown in brackets), in which the SEM values were x/1.5. 104E, TEPC-183). By a Limulus amebocyte lysate method (Asso- would express identical surface phenotypes. Small resting ciates of Cape Cod) the levels of endotoxin were -10 ng per 30 BALB/c splenic B cells were placed in culture with either 10 ,ug of F(ab')2 for goat anti-mouse and rabbit anti-mouse prepa- ,ug of F(ab')2 of rabbit anti-IgM per ml or 10 ng of Fab rations. Cells producing the fusion protein CD40L-CD8 (13) were fragments of the same antibody per ml together with CDC35 from Peter Lane (Basel Institute for Immunology). Supernate T-helper 2 cells specific for Fab. Both treatments induced containing recombinant CD40L produced optimal proliferation B-cell proliferation (experiments DS-4 and DS-9, Table 1), cell when used at a final dilution of 1:2. For thymidine incorporation cells were cultured in 96-microwell plates in 200 ,ul of medium. enlargement, and increased levels of surface CD44 (Fig. 1), For cytometric analysis the cells were cultured in bulk. In both events previously described in association with lymphocyte cases they were established at a density of 1 x 106 per ml. Fresh activation (15). Culture with Fab or T cells alone did not or fixed T cells were added at 1 x 106 cells per ml. Fresh T cells induce proliferation (Table 1), nor was any change in B-cell were irradiated to a total dose of3600 rads (1 rad = 0.01 Gy) from surface CD5 or CD23 seen (data not shown). F(ab')2-treated a cesium source before being placed in culture with the B cells.
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Calreticulin—Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance As a Prognostic Biomarker in Ovarian
    cells Review Calreticulin—Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients Michal Kielbik *, Izabela Szulc-Kielbik and Magdalena Klink Institute of Medical Biology, Polish Academy of Sciences, 106 Lodowa Str., 93-232 Lodz, Poland; [email protected] (I.S.-K.); [email protected] (M.K.) * Correspondence: [email protected]; Tel.: +48-42-27-23-636 Abstract: Immunogenic cell death (ICD) is a type of death, which has the hallmarks of necroptosis and apoptosis, and is best characterized in malignant diseases. Chemotherapeutics, radiotherapy and photodynamic therapy induce intracellular stress response pathways in tumor cells, leading to a secretion of various factors belonging to a family of damage-associated molecular patterns molecules, capable of inducing the adaptive immune response. One of them is calreticulin (CRT), an endoplasmic reticulum-associated chaperone. Its presence on the surface of dying tumor cells serves as an “eat me” signal for antigen presenting cells (APC). Engulfment of tumor cells by APCs results in the presentation of tumor’s antigens to cytotoxic T-cells and production of cytokines/chemokines, which activate immune cells responsible for tumor cells killing. Thus, the development of ICD and the expression of CRT can help standard therapy to eradicate tumor cells. Here, we review the physiological functions of CRT and its involvement in the ICD appearance in malignant dis- ease. Moreover, we also focus on the ability of various anti-cancer drugs to induce expression of surface CRT on ovarian cancer cells. The second aim of this work is to discuss and summarize the prognostic/predictive value of CRT in ovarian cancer patients.
    [Show full text]
  • Immunopharmacology
    Institute of Pharmacology http://www.pki.unibe.ch/ PKI Immunopharmacology Prof. Dr. Stephan von Gunten MD PhD MME Lectures: Clinical Immunology Immunomodulation Endogenous or exogenous molecules that influence immune responses positively (immunostimulation) or negatively (immunoregulation) DC Based Vaccination Freund complete adjuvans (FCA) Freund incomplete adjuvans (FIA) (mycobacteria + mineral oils) (mineral oils, without mycobacteria) differential maturation alum (hydrated alumina) dendritic cell (DC) mycobacteria Toll-like Receptors alum, mineral NLR-Inflammasome oils in FCA/FIA Toll-Like Receptors PAMPs 2 major adapters: MyD88 and TRIF protein kinases transcription factor (NFkB, IRF-3/-7) [IRF: Interferon regulatory factor] gene transcription: inflammatory cytokines, IFNa/b, others BMSc Pharma Immuno Manicassamy S & Pulendran B, Seminars in Immunology 2009 (modified) TLR Agonists and Cancer Immunotherapy: BCG-CWS BCG: Bacillus Calmette-Guérin, attenuated form of Mycobacterium bovis CWS (cell-wall skeleton ): major adjuvant–active part of mycobacterial cells; contains muramyldipeptide (MDP) -> activation of TLR-2 and -4 and NOD2 BCG-CWS TLR-2 MyD88-pathway mDC cytokines CTL tumour cell killing Carbohydrate-based vaccines in development Infectious disease Infectious Cancer Astronomo RD & Burton DR Nat Rev Drug Discov 2016 (modified) Antibody repertoire: glycan immunogenicity linked to structure Schneider et al. Sci Transl Med 2015 Cancer Immunotherapy Galluzi L et al. Oncotarget 2014 Siglec expression on immune cells Jandus C et al. Biochem Pharmacol 2011 Illustration by Aldona von Gunten The sialoglycan shield Jandus C & Boligan KF et al. J Clin Invest. 2014 Siglecs on CD8 T cells? May 2019 Cover Story American Association of Cancer Research (AACR) Immunomodulation Endogenous or exogenous molecules that influence immune responses positively (immunostimulation) or negatively (immunoregulation) Antiinflammatory vs.
    [Show full text]
  • The Immunophilins, Fk506 Binding Protein and Cyclophilin, Are Discretely Localized in the Brain: Relationship to Calcineurin
    NeuroscienceVol. 62,NO. 2, pp. 569-580,1994 Elsevier Sctence Ltd Copyright 0 1994 IBRO Pergamon 0306-4522(94)E0182-4 Printed in Great Britain. All rights reserved 0306-4522194 $7.00 + 0.00 THE IMMUNOPHILINS, FK506 BINDING PROTEIN AND CYCLOPHILIN, ARE DISCRETELY LOCALIZED IN THE BRAIN: RELATIONSHIP TO CALCINEURIN T. M. DAWSON,*t J. P. STEINER,* W. E. LYONS,*11 M. FOTUHI,* M. BLUE? and S. H. SNYDER*f§l Departments of *Neuroscience, tNeurology, $Pharmacology and Molecular Sciences, and §Psychiatry, Johns Hopkins University School of Medicine, 725 N. Wolfe Street, Baltimore, MD 21205, U.S.A. (IDivision of Toxicological Science, Johns Hopkins University School of Hygiene and Public Health Abstract-The immunosuppressant drugs cyclosporin A and FK506 bind to small, predominantly soluble proteins cyclophilin and FK506 binding protein, respectively, to mediate their pharmacological actions. The immunosuppressant actions of these drugs occur through binding of cyclophilin-cyclosporinA and FK506 binding protein-FK506 complexes to the calcium-calmodulin-dependent protein phosphatase, calcineurin, inhibiting phosphatase activity, Utilizing immunohistcchemistry, in situ hybridization and autoradiography, we have localized protein and messenger RNA for FKS06 binding protein, cyclophilin and calcineurin. All three proteins and/or messages exhibit a heterogenous distribution through the brain and spinal cord, with the majority of the localizations being neuronal. We observe a striking co-localiz- ation of FK506 binding protein and calcineurin in most
    [Show full text]
  • Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries with Limited Resources and for Triaging Cases Before
    AJCP /ORIGINAL ARTICLE Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries With Limited Resources and for Triaging Cases Before Referral to Specialist Centers Downloaded from https://academic.oup.com/ajcp/article-abstract/145/5/687/2195691 by World Health Organization user on 09 January 2019 Maria Giulia Disanto, MD,1 Maria Raffaella Ambrosio, MD, PhD,2 Bruno Jim Rocca, MD, PhD,2 Hazem A. H. Ibrahim, FRCPath, PhD,1,3 Lorenzo Leoncini, MD, PhD,2 and Kikkeri N. Naresh, MD, FRCPath1 From the 1Department of Histopathology, Imperial College Healthcare NHS Trust & Imperial College, London, United Kingdom; 2Department of Medical Biotechnologies, Section of Pathology, University of Siena, Siena, Italy; and 3Department of Histopathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Key Words: Lymphoma; B-cell lymphoma; Immunohistochemistry; Diagnosis; Classification; Developing countries Am J Clin Pathol May 2016;145:687-695 DOI: 10.1093/AJCP/AQW060 ABSTRACT Lymphomas are a collection of different malignancies “arising” from lymphoid cells. They include about 49 entities, Objectives: Establish and validate optimal minimal and over 19 provisional entities and subsets.1 About 85% of immunohistochemistry panels for usage in a staged lymphomas are of B-cell origin. Precision in lymphoma diag- algorithmic manner for precise diagnosis of B-cell nosis requires expertise and infrastructure. The entities are lymphomas in countries with limited resources. Suggest defined based on morphology, immunohistochemistry (on short panels of immunostains to be used in referring units some occasions in situ hybridization), cytogenetics/fluores- that refer suspected lymphomas to specialist diagnostic cent in situ hybridization (FISH), molecular genetics and clin- centers in resourceful countries.
    [Show full text]
  • RA0358-C.5-IFU-RUO CD57 / B3GAT1 (Natural Killer Cell
    Instructions For Use RA0 35 8-C.5 -IFU -RUO Revision: 1 Rev. Date: Dec. 19, 2014 Page 1 of 2 P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 – Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com CD57 / B3GAT1 (Natural Killer Cell Marker); Clone NK/804 (Concentrate) Availability/Contents: Item # Volume RA0358-C.5 0.5 ml Description: Species: Mouse Immunogen: Recombinant human B3GAT1 protein Clone: NK/804 Isotype: IgM, kappa Entrez Gene ID: 27087 (Human) Hu Chromosome Loc.: 11q25 Synonyms: 3-Glucuronyltransferase 1; B3GAT1; Galactosylgalactosylxylosylprotein 3-beta- Glucuronosyltransferase 1; GLCATP; GlcUAT-P; Glucuronosyltransferase P; UDP GlcUA Glycoprotein beta 1, 3 Glucuronyltransferase. Mol. Weight of Antigen: ~110kDa Format: Bioreactor Concentrate with 0.05% Azide. Specificity: Anti-CD57 marks a subset of lymphocytes known as natural killer (NK) cells. Anti-CD57 also stains neuroendocrine cells and their derived tumors, including carcinoid tumors and medulloblastoma. Background: Follicular center cell lymphomas often contain many NK cells within the neoplastic follicles. Anti- CD57 can be useful in separating type B3 thymoma from thymic carcinoma when combined with a panel that includes antibodies against GLUT1, CD5, and CEA. Species Reactivity: Human. Does not react with Rat. Others not known. Positive Control: Lymph node or tonsil. Cellular Localization: Cell surface Titer/ Working Dilution: Immunohistochemistry (Frozen and Formalin-fixed): 1:50-1:100 Flow Cytometry: 5-10 µl/million cells Immunofluorescence: 1:50-1:100 Western Blotting: 1:100-1:200 Microbiological State: This product is not sterile. 8° C Storage: 2° C C ScyTek Laboratories, Inc. 205 South 600 West P EmergoEurope (31)(0) 70 345-8570 Logan, UT 84321 Molsnstraat 15 Doc: IFU-Template2-8rev2 U.S.A.
    [Show full text]
  • Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367
    Medicare Local Coverage Determination Policy Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367 CMS Policy for Alaska, Arizona, Idaho, Montana, North Dakota, Medically Supportive Oregon, South Dakota, Utah, Washington, and Wyoming ICD Codes are listed Local policies are determined by the performing test location. This is determined by the state on subsequent page(s) in which your performing laboratory resides and where your testing is commonly performed. of this document. Coverage Indications, Limitations, and/or Medical Necessity Flow cytometry (FCM) is a complex process to examine blood, body fluids, CSF, bone marrow, lymph node, tonsil, spleen and other solid tissues. The use of peripheral blood and fine needle aspirate material avoids more invasive procedures for diagnosis. A flow cytometer evaluates the physical and/or chemical characteristics of single cells as the cells pass individually in a fluid stream through a measuring device. Surface receptors, intracellular molecules, and DNA bind with fluorescent dyes that allow detection and evaluation. When light of one wave length excites electrons of certain chemicals to energy levels above their ground state and upon return to ground state emits light of a longer wavelength, fluorescence is produced. A flow cytometer detects cell characteristics by measuring the fluorescence produced by fluorochromes conjugated either directly with cell components or conjugated to antibodies directed against cell components. Indications • Cytopenias and Hypercellular Hematolymphoid Disorders Hematolymphoid neoplasia can present with cytopenias (anemia, leucopenia and/or thrombocytopenia) or elevated leukocyte counts. If medical review and preliminary laboratory testing fails to reveal a cause, bone marrow aspiration and biopsy are indicated to rule out an infiltrative process or a stem cell disorder.
    [Show full text]
  • CD3+CD5+CD4-CD8-) Alpha/Beta T Cell Receptor-Bearing Cells
    Mlsa generated suppressor cells. I. Suppression is mediated by double-negative (CD3+CD5+CD4-CD8-) alpha/beta T cell receptor-bearing cells. This information is current as of October 2, 2021. M Bruley-Rosset, I Miconnet, C Canon and O Halle-Pannenko J Immunol 1990; 145:4046-4052; ; http://www.jimmunol.org/content/145/12/4046 Downloaded from Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription by guest on October 2, 2021 Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1990 by American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. 0022-1767/90/14512-4046$02.00/0 THEJOURNAL OF IMMUNOLCGY Vol. 145.4046-4052. No. 12. December 15. 1990 Copyright 0 1990 by The American Association of lmmunologists Printed In U.S.A. Mls" GENERATED SUPPRESSORCELLS I. Suppression is Mediated by Double-Negative (CD3+CDVCD4-CD8-) a/@ T Cell Receptor-Bearing Cells' Grafting of cells from B10.D2 (H-2d)donors into H- The GVHR3 remains a major problem after bone mar- 2 compatible lethally irradiated (DBA/2 x B1O.DZ)Fl row transplantation, even in MHC-compatible donor-re- hostsresults in a severe graft-vs-host reaction cipient combinations.
    [Show full text]
  • TLR-Mediated Activation Pathways Calcineurin Negatively Regulates
    Calcineurin Negatively Regulates TLR-Mediated Activation Pathways Young Jun Kang, Brenda Kusler, Motoyuki Otsuka, Michael Hughes, Nobutaka Suzuki, Shinobu Suzuki, Wen-Chen Yeh, This information is current as Shizuo Akira, Jiahuai Han and Patricia P. Jones of September 26, 2021. J Immunol 2007; 179:4598-4607; ; doi: 10.4049/jimmunol.179.7.4598 http://www.jimmunol.org/content/179/7/4598 Downloaded from References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/179/7/4598.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Calcineurin Negatively Regulates TLR-Mediated Activation Pathways1 Young Jun Kang,2,3* Brenda Kusler,* Motoyuki Otsuka,† Michael Hughes,* Nobutaka Suzuki,‡ Shinobu Suzuki,‡ Wen-Chen Yeh,‡ Shizuo Akira,§ Jiahuai Han,† and Patricia P.
    [Show full text]
  • Ligand for Bovine CD5 the Identification and Characterization of A
    The Identification and Characterization of a Ligand for Bovine CD5 Karen M. Haas and D. Mark Estes This information is current as J Immunol 2001; 166:3158-3166; ; of September 27, 2021. doi: 10.4049/jimmunol.166.5.3158 http://www.jimmunol.org/content/166/5/3158 Downloaded from References This article cites 46 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/166/5/3158.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 27, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Identification and Characterization of a Ligand for Bovine CD51 Karen M. Haas* and D. Mark Estes2*† CD5, a type I glycoprotein expressed by T cells and a subset of B cells, is thought to play a significant role in modulating Ag receptor signaling. Previously, our laboratory has shown that bovine B cells are induced to express this key regulatory molecule upon Ag receptor cross-linking.
    [Show full text]
  • How HIV-1 Gag Manipulates Its Host Cell Proteins: a Focus on Interactors of the Nucleocapsid Domain
    viruses Review How HIV-1 Gag Manipulates Its Host Cell Proteins: A Focus on Interactors of the Nucleocapsid Domain 1 2, 2, 2 1 Jéromine Klingler , Halina Anton y, Eléonore Réal y, Manon Zeiger , Christiane Moog , Yves Mély 2 and Emmanuel Boutant 2,* 1 INSERM UMR_S 1109, Centre de Recherche en Immunologie et Hématologie, Faculté de Médecine, Université de Strasbourg, 67000 Strasbourg, France; [email protected] (J.K.); [email protected] (C.M.) 2 UMR 7021, CNRS, Laboratoire de Bioimagerie et Pathologies, Université de Strasbourg, Faculté de Pharmacie, 67400 Illkirch, France; [email protected] (H.A.); [email protected] (E.R.); [email protected] (M.Z.); [email protected] (Y.M.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 13 July 2020; Accepted: 10 August 2020; Published: 13 August 2020 Abstract: The human immunodeficiency virus (HIV-1) polyprotein Gag (Group-specific antigen) plays a central role in controlling the late phase of the viral lifecycle. Considered to be only a scaffolding protein for a long time, the structural protein Gag plays determinate and specific roles in HIV-1 replication. Indeed, via its different domains, Gag orchestrates the specific encapsidation of the genomic RNA, drives the formation of the viral particle by its auto-assembly (multimerization), binds multiple viral proteins, and interacts with a large number of cellular proteins that are needed for its functions from its translation location to the plasma membrane, where newly formed virions are released. Here, we review the interactions between HIV-1 Gag and 66 cellular proteins.
    [Show full text]
  • Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects
    Journal of Immunology Research Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects Guest Editors: Roberta Castriconi, Barbara Savoldo, Daniel Olive, and Fabio Pastorino Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects Journal of Immunology Research Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects Guest Editors: Roberta Castriconi, Barbara Savoldo, Daniel Olive, and Fabio Pastorino Copyright © 2016 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Journal of Immunology Research.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board B. D. Akanmori, Congo Eung-Jun Im, USA G. Opdenakker, Belgium Stuart Berzins, Australia Hidetoshi Inoko, Japan Luigina Romani, Italy Kurt Blaser, Switzerland Peirong Jiao, China Aurelia Rughetti, Italy Federico Bussolino, Italy Taro Kawai, Japan Takami Sato, USA N. G. Chakraborty, USA Hiroshi Kiyono, Japan Senthamil Selvan, USA Robert B. Clark, USA Shigeo Koido, Japan Naohiro Seo, Japan Mario Clerici, Italy Herbert K. Lyerly, USA Ethan M. Shevach, USA Nathalie Cools, Belgium Enrico Maggi, Italy George B. Stefano, USA Mark J. Dobrzanski, USA Mahboobeh Mahdavinia, USA T. J. Stewart, Australia Nejat K. Egilmez, USA Eiji Matsuura, Japan J. Tabarkiewicz, Poland Eyad Elkord, UK C. J. M. Melief, The Netherlands Ban-Hock Toh, Australia S. E. Finkelstein, USA Chikao Morimoto, Japan Joseph F. Urban, USA Luca Gattinoni, USA Hiroshi Nakajima, Japan Xiao-Feng Yang, USA David E. Gilham, UK Toshinori Nakayama, Japan Qiang Zhang, USA Douglas C.
    [Show full text]